Pharming Group N.V.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Fabrice Chouraqui
- Full Time Employees
- 407
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Darwinweg 24 Leiden ZH Netherlands 2333 CR
- IPO Date
- Dec 23, 2020
- CIK
- 0001828316
- Website
- pharming.com
- Similar Companies
- Business
- Pharming Group N.V. (Euronext Amsterdam: PHARM; Nasdaq: PHAR) is a global biopharmaceutical company that develops, manufactures and commercializes innovative protein replacement therapies and precision medicines, including recombinant biologics and small molecules, for patients with rare, debilitating and life-threatening diseases such as hereditary angioedema, primary immunodeficiencies and mitochondrial disorders; its lead marketed products include RUCONEST (conestat alfa), a recombinant C1 esterase inhibitor approved by the FDA, EMA and MHRA for treatment of acute attacks in adult and adolescent patients with hereditary angioedema, and JOENJA (leniolisib), an oral small molecule PI3Kδ inhibitor approved by the FDA and MHRA for activated phosphoinositide 3-kinase delta syndrome. The company advances a pipeline encompassing leniolisib for expanded indications in primary immunodeficiencies with immune dysregulation, including common variable immunodeficiency and genetically identifiable conditions like ALPS-FAS and PTEN deficiency in ongoing Phase II trials, and KL1333, a small molecule for genetically confirmed primary mitochondrial diseases in a pivotal FALCON study that achieved positive interim analysis. Founded in 1988 and headquartered in Leiden, the Netherlands, with U.S. operations in Warren, New Jersey, Pharming serves patients in over 30 markets across North America, Europe, the Middle East, Africa and Asia-Pacific through subsidiaries like Pharming Technologies B.V. Recent developments include the full acquisition of Abliva AB in 2025, increasing ownership to 100% via a compulsory procedure following a tender offer, alongside a 15% reduction in general and administrative expenses announced in May 2025 to optimize capital allocation, revenue guidance increases driven by JOENJA progress, and strategic focus on immunology, hematology and pipeline expansion leveraging its transgenic platform.
Company News
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Ratio makes improved bid for Pharos Energy
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Pharming Group N.V. (PHAR) Shareholders Who Lost Money -- Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Pharming Group N.V. (PHAR) Shareholders Who Lost Money – Contact Law Offices of Howard G.
Securities Fraud Investigation Into Pharming Group N.V. (PHAR) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R.
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Pharming Group (PHAR)
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
Pharming Group Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Pharming Group (PHAR)
Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript
Pharming Group Q2 Earnings Call Highlights
Analysts Set Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Target Price at $38.33
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS
Pharming Group announces results of 2026 Annual General Meeting of Shareholders
Pharming Group Q1 Earnings Call Highlights
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript